Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II azacitidine + valproic acid with optional all-trans retinoic acid for MDS and related myeloid malignancies
ISRCTN92868457Phase 2Completed
- Sponsor
- Heinrich Heine University Düsseldorf
- Start
- Mar 2007
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azacitidine, valproic acid and tretinoin in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML), sponsored by Heinrich Heine University Düsseldorf. Primary endpoint: Safety/toxicity. Started Mar 2007; status: completed.
02
Drugs
azacitidinevalproic acidtretinoin
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ISRCTN92868457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN92868457.